Which BTK inhibitor for mantle cell lymphoma, on 70 studies and no head-to-head trial

Design

Systematic review and meta-analysis pooling randomised and single-arm studies, searched to January 2025

Population

70 studies of ibrutinib, acalabrutinib or zanubrutinib in treatment-naive and relapsed or refractory mantle cell lymphoma

Primary outcome

Pooled complete response rate by drug, line of therapy and regimen, with haematological toxicity

Effect

Complete response 76.5% treatment-naive vs 43.2% relapsed; zanubrutinib-containing first line 95.2% (95% CI 0.893-1.000, p=0.0042); acalabrutinib monotherapy 43.2% (0.339-0.525) in relapsed disease

Ibrutinib, acalabrutinib and zanubrutinib are all used in mantle cell lymphoma and have never been compared directly. This meta-analysis pooled 70 studies - randomised and single-arm - to see what can be said in their absence.

Complete response was 76.5% in treatment-naive disease and 43.2% in relapsed or refractory disease. Among treatment-naive patients, zanubrutinib-containing regimens reached a pooled complete response of 95.2% (95% CI 0.893-1.000), significantly higher than acalabrutinib- or ibrutinib-containing regimens (p=0.0042). In relapsed disease the best results came from a BTK inhibitor combined with an anti-CD20 antibody and a further small molecule (68.3%, 0.546-0.820). Comparing monotherapies in relapsed disease, acalabrutinib gave the highest complete response (43.2%, 0.339-0.525). Zanubrutinib-based therapy had the lowest pooled haematological toxicity.

The methodological warning has to be stated clearly, because the conclusions read like a ranking. Pooling single-arm studies and comparing the pooled rates across drugs is not a randomised comparison - the patients enrolled in a zanubrutinib study differ from those enrolled in an ibrutinib study a decade earlier, in age, prior lines and in how response was assessed. A complete response rate of 95.2% with an upper confidence bound of 1.000 signals a small number of patients, not a near-perfect drug.

What it supports is modest and useful: the newer, more selective inhibitors are not worse than ibrutinib and are better tolerated, which is consistent with the randomised evidence in other B-cell malignancies. That is enough to prefer them where all three are available and priced comparably. In India, availability and cost will settle it more often than efficacy data will.

• Prefer a more selective BTK inhibitor where cost and availability allow - the tolerability signal is consistent
• Do not read the pooled response rates as a head-to-head ranking; no such trial exists
• Chemotherapy-free combinations performed best in relapsed disease and deserve trial evaluation
• Check cardiac history and bleeding risk before starting any BTK inhibitor, whichever you choose
• A 95.2% pooled response with an upper bound of 100% means few patients, not near-certain response

The statistics, in plain English

Comparing pooled rates from separate single-arm studies is the weakest form of comparison available: any difference between drugs is entangled with differences between the populations that received them and the eras in which they were studied. A confidence interval reaching 1.000, as zanubrutinib's does, means the data cannot exclude a 100% response rate - which is a statement about how few patients were pooled, not about the drug. The relapsed-disease combination result, 68.3% with an interval of 54.6-82.0%, is wide for the same reason.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.